|
|||||
|
|
| Latest Insider Trading | Top Insider Trading Recent Week | Top 10% Owner Trading Recent Week | Filter
|
| Ticker | Owner | Relationship | Date | Transaction | Cost |
#Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| BBIO | HOMCY CHARLES J | Director | Aug 08 '25 | Sale | 46.05 | 250,000 | 11,512,443 | 966,674 | Aug 12 07:06 PM |
| BBIO | HOMCY CHARLES J | Director | Aug 11 '25 | Sale | 48.00 | 50,000 | 2,400,000 | 916,674 | Aug 12 07:06 PM |
| BBIO | CHARLES J HOMCY | Director | Aug 11 '25 | Proposed Sale | 48.00 | 50,000 | 2,400,000 | Aug 11 04:17 PM | |
| BBIO | CHARLES J HOMCY | Director | Aug 08 '25 | Proposed Sale | 46.05 | 250,000 | 11,512,420 | Aug 08 05:11 PM | |
| BBIO | HOMCY CHARLES J | Chairman of Pharmaceuticals | Oct 16 '20 | Option Exercise | 17.00 | 10,256 | 174,352 | 1,214,023 | Oct 19 09:14 PM |
| BBIO | HOMCY CHARLES J | Chairman of Pharmaceuticals | Oct 16 '20 | Sale | 41.00 | 10,256 | 420,496 | 1,203,767 | Oct 19 09:14 PM |
| BBIO | HOMCY CHARLES J | Chairman of Pharmaceuticals | Sep 30 '20 | Option Exercise | 17.00 | 10,000 | 170,000 | 1,213,767 | Oct 01 04:05 PM |
| BBIO | HOMCY CHARLES J | Chairman of Pharmaceuticals | Sep 30 '20 | Sale | 38.00 | 10,000 | 380,000 | 1,203,767 | Oct 01 04:05 PM |
| BBIO | HOMCY CHARLES J | Chairman of Pharmaceuticals | Sep 25 '20 | Sale | 36.83 | 81,057 | 2,985,455 | 1,221,967 | Sep 29 07:02 PM |
| BBIO | HOMCY CHARLES J | Chairman of Pharmaceuticals | Sep 29 '20 | Sale | 37.50 | 18,200 | 682,500 | 1,203,767 | Sep 29 07:02 PM |
| BBIO | HOMCY CHARLES J | Chairman of Pharmaceuticals | Feb 10 '20 | Sale | 36.00 | 20,000 | 720,000 | 1,342,291 | Feb 12 07:03 PM |
| BBIO | HOMCY CHARLES J | Chairman of Pharmaceuticals | Jan 14 '20 | Option Exercise | 17.00 | 10,000 | 170,000 | 1,372,291 | Jan 16 07:17 PM |
| BBIO | HOMCY CHARLES J | Chairman of Pharmaceuticals | Jan 14 '20 | Sale | 35.00 | 10,000 | 350,000 | 1,362,291 | Jan 16 07:17 PM |
Join thousands of traders who make more informed decisions with our premium features. Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite